Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes Mellitus
The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin glargine on lowering the blood sugar level.
- Trial name
- NCT00447213
- Testing
- Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin
- Where
- 5 sites in Japan, Taiwan
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (BiAsp 30) thrice daily treatment with that of a basal-bolus treatment…
- Trial name
- NCT00824668
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin glulisine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 1
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction
- Trial name
- PORTAL 1 (NCT00964574)
- Testing
- INSULIN GLULISINE (HMR1964), INSULIN GLARGINE
- Where
- Belarus
- Volunteers
- 68 people
- Sponsor
- Sanofi
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 1 Diabetes
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin…
- Trial name
- NCT07282054
- Testing
- THDB0206, Insulin Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes, Healthy
Within-subject Variability of Insulin Detemir in Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of insulin detemir to that of another basal insulin analogue, insulin glargine in healthy volunteers.
- Trial name
- NCT01497535
- Testing
- insulin detemir, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
- Trial name
- NCT00135083
- Testing
- insulin glulisine
- Volunteers
- 347 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study in Adults With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
- Trial name
- ELEMENT 2 (NCT01421459)
- Testing
- LY2963016, Lantus, OAMs
- Where
- 62 sites in United States, Czechia and 10 more
- Volunteers
- 759 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
Primary objective: Efficacy assessment of the percentage of positive responders patients receiving Lantus plus glucophage association.
- Trial name
- GALATEE (NCT00653302)
- Testing
- Lantus (insulin glargine) + Glucophage (Metformin)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients
Primary objectives: To demonstrate biosimilarity with regard to the total and maximum pharmacokinetic exposure during one dosing interval (AUC ins. 0-24h, Cins.
- Trial name
- NCT04236895
- Testing
- Gan & Lee Insulin Glargine Injection
- Where
- 2 sites in Germany
- Volunteers
- 114 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Renal Impairment
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment.
- Trial name
- TRENT (NCT05552859)
- Testing
- Insulin glargine 300 U/mL, Insulin degludec 100 U/mL
- Where
- 68 sites in United States, Czechia and 3 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared.
- Trial name
- NCT03951805
- Testing
- Insulin icodec, Insulin Glargine
- Where
- 43 sites in United States, Croatia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Insulin Glulisine, Diabetes Mellitus Type 1
To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy
- Trial name
- NCT00397553
- Testing
- Insulin glulisine
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02479022
- Testing
- Insulin 320, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company